|
|
| | </script> | | </script> |
| | </head> | | </head> |
| − | <h2> The light at the end of the tunnel...</h2> | + | <!-- Start of content --> |
| | | | |
| − | <p>Cancer diagnosis is one of modern medicine's major and challenging problems<sup>1</sup>. Thus, designing a novel method to test for cancer cells quickly caught our attention as a potential project idea. After researching current testing methods and brainstorming how a test could be implemented in a genetically-modified organism, we came up with a system for the assessment of metastasis risk in cancer patients and high-risk groups using a genetically-engineered strain of <i>Escherichia coli</i> which we call MicroBeacon <i>E. coli</i>.</p> | + | <div class="expContainer" style=position:relative> <!--The closing tag for contentContainer should be placed at the bottom of each content page.--> |
| | | | |
| − | <p>Circulating tumour cells (CTCs) can be used as an indicator of the initial stages of metastasis<sup>2</sup>. In our project we aim to develop a novel method that is fast, economical, and reliable for the identification of CTCs by using MicroBeacons to detect two general cancer markers and indicate this through fluorescence. By design, this makes our system applicable to many types of cancer. To facilitate handling the cells, our detection system will be embedded in a microfluidic chip built especially for this purpose. In contrast to existing methods which rely on detection of very specific cancer markers<sup>3,4,5</sup>, a single general test would be more economical if it can be mass produced and deployed in a cost-effective manner.</p> | + | <h1> A Microbial Beacon for Cancer Detection </h1> |
| | | | |
| − | <p>The first marker we are planning to detect is the increased production rate of lactate by cancer cells due to the Warburg effect, a metabolic shift occurring in tumor cells that is characterized by a much higher glycolysis rate and subsequent lactic acid fermentation<sup>6,7</sup>. The constitutive expression of LldR, a repressor of the lldPRD operon in <i>E. coli</i>, is an important part of our method. Binding of lactate to LldR causes a conformational change inhibiting its ability to bind to its target operators and activating the operon<sup>8</sup>. Due to the accumulation of lactate over time in the environment, we designed our sensor to detect fold-changes instead of a concentration threshold using a gene expression system with an incoherent feedforward loop topology<sup>9</sup>. Overall, a newly designed lldR-lacO fusion promoter acts as a filter which will only allow the production of quorum sensing molecules (AHL) if an elevated lactate production rate is detected. This is where the second cancer marker comes into play.</p> | + | <!--[if gte IE 9]><!--> |
| | + | <!--<div class="imgBox">--> |
| | + | <object class="svg" data="https://static.igem.org/mediawiki/2015/7/74/Description.svg" type="image/svg+xml" width="12%"> |
| | + | </object> |
| | + | <!--</div>--> |
| | + | <!--<![endif]--> |
| | + | <!--[if lte IE 8]> |
| | + | <![endif]--> |
| | | | |
| − | <p>For the second signal, apoptosis is induced only in cancer cells by incubating the sample in a solution containing soluble TNF-related apoptosis-inducing ligand (sTRAIL) prior to the introduction of MicroBeacons to the environment<sup>10</sup>. The initiation of apoptosis can then be detected by the strong binding of Annexin V to phosphatidylserine (PS) that appears on the outer membrane of the target CTCs<sup>11</sup>. Although it is normally an intracellular protein<sup>12</sup>, we plan to engineer it to be expressed on the surface of our MicroBeacons, allowing them to bind to the target CTCs. Co-localisation of several MicroBeacons on the surface of an apoptotic CTC will be detected via quorum sensing signals which are only initiated upon detection of elevated lactate levels. The final output of the system is the expression of reporter green fluorescent protein (GFP) coupled to this quorum sensing system, which should only be significantly expressed near a target if it is a cancer cell.</p> | + | <h3>Cancer as a major health concern</h2> |
| | + | </html> |
| | + | [[File:ETH15_cancer_top10_killer.png|thumb|1000px|<b>Figure 1.</b> Cancer is a leading cause of death among high income countries. Image from <html><a href="http://www.who.int/mediacentre/factsheets/fs310/en/index1.html">WHO</a></html>]] |
| | + | <html> |
| | | | |
| − | <p>Overall, the integration of two general markers allows for the detection of various types of cancers with high reliability and a low false positive rate, while control of signal expression by the bacteria should result in a considerable increase in the signal to noise ratio compared to assay kit-based tests. The direct binding of our MicroBeacons to cancer cells allow for the detection of lactate and AHL in a very controlled microenvironment with minimal crosstalk from other cells in the sample or unbound MicroBeacons. Finally, the use of a fluorescent signal as our output signal will allow for easy measurement from the microfluidic chip through microscopy.</p> | + | <p>Cancer is among the top ten causes of death in developed countries [<a href="http://www.who.int/mediacentre/factsheets/fs310/en/index1.html">WHO</a>]. Amongst all cancer patients, for approximately 90% the ultimate cause of death is metastasis [<a href="https://2015.igem.org/Team:ETH_Zurich/References#Saxe2013">Saxe 2013</a>], be it during the initial occurrence of cancer or at a time after successful treatment [<a href="https://2015.igem.org/Team:ETH_Zurich/References#Cooperberg2009">Cooperberg 2009</a>]. Therefore, early diagnosis of metastasis is one of modern medicine's major and challenging problems [<a href="https://2015.igem.org/Team:ETH_Zurich/References#WHO2014">WHO 2014</a>]. Thus, designing a novel method to test for <a href="https://2015.igem.org/Team:ETH_Zurich/Glossary#Circulating_Tumor_Cell__CTC_">Circulating Tumor Cells (CTC)</a>, which represent the first sign of possible metastasis [<a href="https://2015.igem.org/Team:ETH_Zurich/References#Sleijfer2007">Sleijfer 2007</a>], quickly caught our attention as a potential project idea. After researching current testing methods we decided to come up with a system for the assessment of metastasis risk in cancer patients and high-risk groups using a genetically engineered strain of <i>Escherichia coli</i>. The big advantage of a bacterial system over conventional analysis methods, such as antibody-based detection or CT scans, is the great capacity of signal integration in genetic circuits and the generation of a robust, yet sensitive output. Our engineered <i>E. coli</i>, called <b>MicroBeacons</b>, will provide a broadly applicable, cheap, and reliable <a href="https://2015.igem.org/Team:ETH_Zurich/Applications">alternative to existing tests</a> for <b>circulating tumor cells (CTC)</b>.</p> |
| | | | |
| | + | <h3>A universally applicable system for CTC detection</h3> |
| | + | <p>Circulating tumor cells (CTCs) can be used as an indicator of the initial stages of metastasis [<a href="https://2015.igem.org/Team:ETH_Zurich/References#Sleijfer2007">Sleijfer 2007</a>]. In our project we aim to <a href="https://2015.igem.org/Team:ETH_Zurich/Design">develop</a> a novel method that is fast, economical, and reliable for the identification of CTCs by using MicroBeacons to detect <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Genetic_circuit">two general cancer markers</a> and indicate their co-occurrence through fluorescence. By design, this makes our system applicable to many types of cancer. To enable <b>single cell analysis</b> and facilitate handling of the the cells, our detection system will be embedded in a microfluidic chip built especially for this purpose. In contrast to existing methods which rely on detection of very specific cancer markers, such as epithelial cell adhesion molecules [<a href="https://2015.igem.org/Team:ETH_Zurich/References#Cooke2001">Cooke 2001</a>, <a href="https://2015.igem.org/Team:ETH_Zurich/References#Garcea2005">Garcea 2005</a>, <a href="https://2015.igem.org/Team:ETH_Zurich/References#Singhal2005">Singhal 2005</a>], a single general test would be more economical if it can be mass produced and deployed in a cost-effective manner. </p> |
| | | | |
| − | <script type="text/javascript"> | + | </html> |
| − | $.get(
| + | [[File:General_system_overview.png|thumb|center|700px|<b>Figure 2.</b> General system Overview: A blood sample will be drwan from a patient and is injected into a microfluidics chip together with our engineered MicroBeacon <i>E. coli</i>. Within the chip, single cell analysis will take place as MicroBeacons identify and bind cancer cells, which results in the generation of a fluorescent signal indicating presence of CTC in the patient's blood.]] |
| − | "https://2015.igem.org/Team:ETH_Zurich/Description/ETH_Zurich_description_overview.svg?action=raw&ctype=text/javascript"
| + | <html> |
| − | , function(response) {
| + | |
| − | document.getElementById('systemOverview').innerHTML = response;
| + | |
| − | });
| + | |
| − | </script>
| + | |
| − | <div id="systemOverview">
| + | |
| − | </div>
| + | |
| | | | |
| | + | <h3>Higher selectivity thanks to AND gate</h3> |
| | + | <p>The elevated lactate production and binding of MicroBeacons on an apoptotic cell lead to a fluorescent signal. Both signals are chained in a way that quorum sensing can only be initiated upon detection of elevated lactate production rates. The final output of the system is the expression of reporter green fluorescent protein (GFP) coupled to this quorum sensing module (see density sensor in figure below), which is only expressed in significant levels near a target if it is a cancer cell.</p> |
| | | | |
Fatal error: Allowed memory size of 134217728 bytes exhausted (tried to allocate 1048576 bytes) in /websites/2015.igem.org/wiki/includes/diff/DairikiDiff.php on line 342